The majority of human cells absorb serum iron during their development. This requirement for iron varies considerably; in cells such as developing marrow normoblasts and placental syncytiotrophoblasts iron is required in large amounts for incorporation into haemoglobin or for transport to the developing fetus. In other cells iron is needed in smaller amounts but is nevertheless essential to normal development.
The first step in cellular iron uptake is binding of transferrin:iron complexes to the cell surface mem- brane. This appears to be mediated by a specific molecule known as the transferrin receptor (TR).
There has recently been considerable interest in this molecule which appears to be expressed in much larger amounts on proliferating cells (compared to cells in the resting state) and on cells which have undergone malignant transformation.' -4 Furthermore TR is similar in several respects to the malignancy-associated glycoprotein reported by Bramwell and Harris.5 The latter molecule is expressed in substantially greater amounts on malignant than on non-malignant cells and is similar to TR in its molecular weight, its disulphide-bonded dimeric structure, its acidic nature, and its pattern of binding to lectins (concavalin A and wheat germ agglutinin).3
Accepted for publication 4 January 1983 Despite these interesting characteristics of the human transferrin receptor refrigerator. Cryostat sections (5-10 Am in thickness) were collected on gelatin-coated glass slides, thoroughly dried (by desiccation for 4-18 h in the vacuum chamber of a freeze drying apparatus) and fixed in acetone for 10 min at room temperature. Sections were then air-dried and either stained immediately by the immunoperoxidase procedure (see below) or else wrapped in aluminium foil and stored at -20'C.
ANTIBODIES
The production of the monoclonal antibody BK19.9, and the evidence for its specificity for human TR has been described previously."4 BK19.9 is of murine origin and was used for immunohistological staining as undiluted tissue culture supernatant. Three other anti-TR monoclonal antibodies, also of murine origin (B3/25, T56/14, T58/1-all from the Salk Institute) of which B3/25 has been extensively characterised2 15 Development of the peroxidase reaction was performed by incubating sections with diaminobenzidine (0-6 mg/ml) and hydrogen peroxide (0-01%) in TBS for 5-10 min at room temperature. Sections were then washed in tap water, counterstained with
Results

NORMAL TISSUES
The immunohistological reaction patterns seen in normal tissues are listed in Table 2 and illustrated in Fig. 1 . The majority of positively labelled cells showed a linear reaction product demarcating the cell surface. In addition diffuse cytoplasmic positivity was also often seen suggesting that TR is present both within and on the surface of positively labelled cells. All four antibodies showed similar patterns of reactivity on most of the tissues tested (Table 2) although BK19.9 gave consistently stronger reactions than the others. There was one clear exception in the case of liver where BK19.9 stained Kupffer cells ( Fig. 2a) and not hepatocytes whereas B3/25, T56/14 and T58/1.4 gave the reverse pattern (Fig.  2b) . The other major difference was that whereas BK19.9 always stained islets of Langerhans in the pancreas extremely clearly (Fig. le) the other three consistently gave much weaker and more patchy labelling.
MALIGNANT TISSUES Antibody BK19.9 A total of 87 neoplastic tissue samples were analysed for the presence of TR by staining with 
Discussion
This study has shown that TR, as detected by four monoclonal antibodies shows a restricted expression pattern in normal human tissue. It is present in the basal layers of squamous epithelium (both keratinising and non-keratinising- Fig. 1 ), but not in more superficial cell layers. Furthermore it is found in the endocrine pancreas (but not the exocrine portion of the gland), in seminiferous tubules of the testis, in the pituitary, in Kupffer cells of the liver (Fig. 2a-BK19 .9 only) and hepatocytes (Fig. 2b-B3 Whatever the underlying reasons for these patterns of TR expression it is striking that they show partial correlation with the sites (skin, pancreas, testis, pituitary, and liver) at which excessive iron deposition occurs in primary haemochromatosis. This suggests that tissues which sustain damage in this disease may be susceptible because of high levels of TR expression. It is not possible, however, solely on the basis of this immunohistological analysis, to assess whether this explanation of the pathogenesis of tissue damage in primary haemachromatosis is valid. It should be noted that at least two sites which are not generally recognised as being particularly susceptible to damage from excess iron deposition were clearly labelled with anti-TR (kidney and gut). A striking finding was that hepatocytes and Kupffer cells both of which are known to express TR"8 gave different labelling patterns with BK19.9 compared to the other three monoclonal anti-TR antibodies (Fig. 2) . The other major difference between BK19.9 and the other antibodies was that whereas BK19.9 stained islets of Langerhans strongly and completely (Fig. le) the others were consistently much weaker and patchier.
The explanation of the fact that four antibodies of apparently identical specificities, gave different immunohistological labelling patterns remains to be elucidated. This discrepancy could reflect the fact that the transferrin receptor is not a single molecular entity but rather a family of molecules which are antigenically similar but not identical. There is a precedent for this in the description'9 of monoclonal antibodies which will distinguish sub-populations of the leucocyte-associated antigen. It is indeed possible that the striking molecular similarity between the transferrin receptor and the malignancy associated antigen5 (see Introduction) may also be explained by the fact that both belong to a family of structurally related but antigenically distinct molecules concerned with molecular binding and transportation-that is, transferrin and glucose respectively. The recently reported "family" of molecules represented by the macrophage antigen MAC-1 and the lymphoid antigen LFA-1202' provides a precedent in this context.
Finally TR was found to be present on the majority of carcinomas, on all sarcomas and on all cases of Hodgkin's disease examined. In contrast nonHodgkin's lymphomas were either weakly labelled or gave (in approximately one third of cases) a negative reaction.
These results should be interpreted in the context of previous studies in animals which have shown a relation between the rate of tumour proliferation, tumour mass and the uptake of transferrin by tumours. 22 This suggests that a relation may exist between TR expression and the growth rate or differentiation of human tumours. This is supported by a recent study showing that anti-transferrin receptor antibody inhibited the growth of human melanoma cells in nude mice.23 However it should be noted that in the present study staining for transferrin receptor was not obviously related to tumour differentiation or mitotic rate, and indeed some secondary tumours were entirely negative for TR (Table 3) . One 
